Please see the first issue of OIS Press with updates on novel ophthalmic therapies. I provide a perspective in recent US FDA approvals (Pages 9 and 11).
- Value of medical writers discussed in top journal
- Client publishes 100th paper – PharmaLogic wrote the first one
- Dr. Novack’s paper among top 100 glaucoma papers
- Unintended consequences of off-label use
- Off-label use: Article in the American Journal of Ophthalmology
- PharmaLogic work contributes to glaucoma therapeutics